Procter & Gamble is seeking FDA approval to sell the testosterone patch Intrinsa, the first such product to treat a condition that affects up to 3 million surgically menopausal American women.
Clinical trials showed that women using Intrinsa had only modest improvements to their sex lives. Women who applied the patch to their abdomen twice weekly had one more "satisfying sexual event" per four weeks, compared with a placebo.
No comments:
Post a Comment